Karyopharm Therapeutics Inc. (KPTI) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| License and Other Revenue | 5.9M | FY2026-Q1 |
| Expovio Net Product Revenue (United States) | 29.16M | FY2026-Q1 |
| Royalties from Partners | 1.9M | FY2026-Q1 |
| Community Setting Share of Expovio Net Product Revenue | 60.00 percent | FY2026-Q1 |
| Expovio Net Product Revenue (United States Commercial Sales) | 32M | FY2025-Q3 |
| Phase Three SENTRY Trial Enrollment Target | 350.00 | FY2025-Q2 |
Back to KPTI overview · KPTI earnings · KPTI holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.